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Interim analysis of Acute Myeloid Leukaemia treated on the Red Cross Children’s 
Hospital Rx 2071 (adapted from the MRC AML 15 protocol) 
 
Background:   
Due to the poor outcomes achieved in acute myeloid leukaemia (AML) treatment, the Red 
Cross War Memorial Children’s Hospital (RCWMCH) Oncology service changed from a 
BFM-87 based protocol
 
to one based on MRC-AML15 in 2007.
 
Rationale: 
This study was designed to assess the outcomes and treatment – related toxicity among 
children treated with RCWMCH protocol Rx 2071.   
Methods: 
This was a retrospective review of AML patients treated with Rx2071 between 2007 and 
2012 at RCWMCH. Patients with acute promyelocytic leukaemia (APL) and Down 
Syndrome were excluded. Risk was assigned by cytogenetics. Good risk patients were those 
with t(8;21), t(16,16) and inv(16). Poor and standard risk included all other cytogenetics 
according to MRC-AML15. Data pertaining to toxicity was obtained from patient folders.  
 Results:  
Thirty five children were treated on Rx 2071 during the study period. Males comprised 
51.4% (18/35) and females 48.6% (17/35). Age at diagnosis ranged from 0.33 to 12.51 years 
with the median being 5.68 years. Follow–up from remission in the patients who survived 
ranged from 1 year 10 months to 9 years 1 month with a median of 62.5 months. Fifteen 
patients had favourable cytogenetics. Event free survival (EFS) for the good risk group was 
85.6%. Twenty patients presented with standard/poor risk cytogenetics. Five patients were 
deemed poor risk with one having major karyotype abnormalities and four not achieving 
remission. The remaining fifteen were deemed standard risk by cytogenetics. EFS in this 
group was 32.4%. 
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Two standard/poor risk patients were transplanted in first complete remission (CR1) and two 
patients were transplanted in second complete remission. (CR2) 
Patients had a median of four neutropaenic fevers, and required a median of eight packed cell 
and eleven platelet transfusions. There were 39 positive blood cultures. Treatment related 
deaths were 8.57%.  
  
Discussion: 
The EFS for good risk patients is excellent but the EFS for standard/poor risk group is not on 
par with results being achieved in high income countries. The toxicity is not excessive on 
Rx2071. The results achieved on this protocol were superior to that of the previous BFM- 
based protocol. 
Conclusion: 
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 1.1 Context: 
Acute myeloid leukaemia (AML) constitutes 15 – 20% of all childhood and adolescent acute 
leukaemia. [1] 
AML is a heterogonous family of neoplasms of the myeloid lineage. [1] The neoplastic cells 
in AML show an increased rate of self-renewal, aberrant differentiation and a decreased rate 
of auto destruction. [1] 
The progress in treating AML has lagged behind that of acute lymphoblastic leukaemia 
(ALL). [2] Prior to 1970 the prognosis of children with AML was dire. [1, 3] A recent paper 
in the Journal of Clinical Oncology showed that five year overall survival (OS) rates in AML 
now range from 50% - 76%. [4] There has, thus been steady progress in the treatment of 
AML. [5,6] 
The history of AML treatment in children is interesting.  Prior to 1970 nearly all patients with 
AML died of their disease. [1] Anthracyclines and cytarabine were introduced alone and in 
combination in the 1970s and 1980s. [1] This lead to a minority of patients being cured. [1] 
The five year survival rate of children younger than fifteen with AML until the early 1990s 
was poor at 28%, [1] but there has been an improvement in the prognosis of AML over the 
last few decades. [5,7] National and international study groups were formed in the 1980s and 
1990s. [4] Their goal was to improve the outcomes among children with cancer through 
cooperative research. [4] These study groups conducted various AML trials which  
intensified the doses of traditional chemotherapeutic agents. [1] The groups used similar 
approaches such as risk adapted treatment and the use of dose intense blocks with common 
drugs such as cytarabine, anthracyclines and etoposide. [7] There were, however, many 
differences among the study groups such as the number, designs and intensity of the 
treatment blocks, cumulative doses of certain drugs, the use of maintenance treatment, 
prophylaxis for central nervous system (CNS) relapse and the use of allogeneic 
haematopoietic stem cell transplantation (allo – HSCT). [7] A key factor in the improvement 
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of AML survival has been the advent of good supportive care which allows for dose intense 
treatment. [4,7] 
The various AML studies have presented numerous questions which were highlighted by the 
late Robert Arceci in a review article. [1] These questions include: what is the optimal 
induction remission regimen?; [1] how many courses of chemotherapy are needed to cure 
AML?; [1] what is the optimal therapy to reduce CNS relapse?; [1] what is the role of  allo - 
HSCT  in first complete remission  (CR1)? [1] and is there a role for maintenance therapy? 
[1] Various collaborative groups have different approaches to these questions. The Berlin 
Frankfurt Munster (BFM) group uses a one year maintenance block. [4,8] Despite the use of 
maintenance, the BFM results are similar to those groups that do not use maintenance 
therapy. [4] Two studies, LAME 91 and CCG 213 looked at the use of maintenance therapy 
in AML and found no benefit. [4,7,9] The new BFM AML trial, AML – BFM 2012 will 
randomly assign patients to maintenance and will assess the possibility that certain sub 
groups will benefit from maintenance. [4]  
 
All studies have experienced success with intensifying doses but there is no consensus on 
how many courses of the chemotherapy are optimal. [1] Many of the study groups use five 
courses of chemotherapy in total with three courses being used for consolidation. [4] The 
United Kingdom’s Medical Research Council (MRC) MRC AML 15 trial showed that four 
courses of chemotherapy were effective. [4,10] This was, however, shown primarily in 
adults. [4] There is no consensus on the optimal approach to central nervous system (CNS) 
prophylaxis in AML. [4]The BFM 87 trial showed that patients receiving cranial irradiation 
had a better relapse – free survival. [1,8] This was in contrast to many other studies such as 
the MRC, Paediatric Oncology Group (POG) and Children’s Cancer Group (CCG) trials. 
These studies did not include cranial radiation and they had similar outcomes to the BFM 87 
trial. [1,11,12] Most study groups are using intrathecal therapy as CNS prophylaxis and have 
moved away from cranial irradiation. [4] 
The role of allo- HSCT in CR1 has led to debate among study groups. [4] Since the mid-
1980s allo- HSCT has been recommended for patients with a matched sibling donor 
following induction chemotherapy. [11,13,14,15] There are no randomized studies comparing 
allo-HSCT to chemotherapy. [6] It is also not possible to do historical comparison of 
outcomes because of the differences in intensity of the chemotherapeutic agents used prior to 
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allo -HSCT. [4] Even though there is no consensus on the use of allo- HSCT, there is broad 
support among European and North American groups to use allo- HSCT in poor risk patients 
in CR1 [4] and there is general consensus among the various study groups that patients with 
acute promyelocytic leukaemia (APL), Down syndrome and those with t(8,21), inv(16) or 
t(16,16) do not need allo – HSCT in CR1. [13,16]  
A recent review article in Journal of Clinical Oncology brought the issue of risk group 
stratification to light. [4] Cytogenetic patterns play a central role in risk stratification in AML. 
[4] There is general consensus among the study groups about the definition of high risk 
disease but groups differ in their definitions of low, standard and intermediate risk groups.[4] 
The following cytogenetic patterns are generally recognised by study groups across the world 
as markers of good risk disease: inversion 16; t(16;16) and t(8;21). [3,5,17] High risk 
cytogenetic patterns include the following: FLT3 mutations, monosomy 7, monosomy 5, 
abnormal 3q and complex karyotype abnormalities. [4,6,7] The European Leukaemia 
Network (ELN) calls for testing of  FLT3 internal tandem duplication (ITD), CEPBA and 
NPM1 to further risk stratify.[18] The ELN deems CEPBA to be good risk whilst patients 
with FLT3ITD and wild type  NPM1 mutations are classified as intermediate risk.[18] A 
bone marrow with >15% blasts after the first induction course is also deemed as poor risk on 
the MRC AML trials. [11] An international expert panel published recommendations on the 
diagnosis and management of AML.[19]  They state that minimal residual disease ( MRD) 
can be monitored and that though some study groups use MRD as part of risk stratification, 
its clinical benefit is still being investigated. [19]   
Another factor contributing to the improved overall survival is better salvage after relapse. 
[20] The BFM group looked at a cohort of 379 patients with relapsed AML and found that a 
third can be salvaged. They recommend HSCT in CR2. [20] 
Robert Arceci suggests that the ideal remission – reduction regimen is one that effectively 
results in cytoreduction without significant toxicity to the patient and one which has a 
positive impact on post remission treatment. [1] AML Studies in the past have shown 
relatively high mortality related to the leukaemia and treatment complications. [4,21] Patients 
with AML are at risk of invasive fungal infections, and viridans streptococcal and gram 
negative bacteraemia. [4,22] AML patients with hyperleukocytosis (white blood cell count > 
100 x 10
9
/L) are at increased risk of pulmonary leukostasis, CNS ischaemia and haemorrhage 




The Red Cross War Memorial Hospital Children’s Hospital (RCWMCH) AML treatment 
protocol, Rx 2941, from 1994 – 2007 was adapted from the BFM- 87 protocol. [23] The 
outcome for the standard/poor risk patients was poor with EFS of 27.3%. [23]The EFS for 
good risk patients was 74.4%. [23] The toxicity related death rate with Rx 2941 was 9%. [23] 
This resulted in a change in the RCWMCH AML treatment protocol and in 2007 an MRC – 
AML 15 based protocol, Rx 2071 was adopted. 
 
The RCWMCH AML protocol Rx2071 has been used since 2007. This study was designed to 
assess the outcomes and treatment – related toxicity among children treated with RCWMCH 
protocol Rx 2071. This study will serve as a base to decide whether or not to continue to treat 
children with AML on Rx 2071. It will also allow us to identify any shortcomings of this 
current protocol.  
1.2 Ethical Considerations: 
This is a retrospective study therefore informed consent from each patient is thought to be 
unnecessary. The names of the patients will not be published or used in any presentations. 
This study implemented the ethical principle of beneficence and non-maleficence. The results 
of this study will benefit future patients with AML because it will determine whether or not 
the current treatment protocol is an improvement on the old regime based on event free 
survival. There were no adverse effects on any subjects due to this study. 
This study will serve as the mini dissertation for an MPhil project and will be put forward for 
publication in a peer review journal.  
Ethics approval was obtained from the University of Cape Town’s Faculty of Health 
Science’s  Human Research Ethics Committee. The ethics reference  number is HREC REF: 
235/2012. (Appendix 2) 
1.3 Journal for Publication 
Pediatric Blood and Cancer (PBC) is the journal selected for publication. PBC has an impact 
factor of 2.634. PBC has a wide readership and publishes relevant research articles pertaining 
to childhood oncological and haematological topics. PBC is listed on the South African 
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Acute myeloid leukaemia (AML) treated on the Red Cross War Memorial Children’s 
Hospital (RCWMCH) Treatment protocol Rx 2071 (adapted from MRC-AML15) 
Background:  
The Red Cross War Memorial Children’s Hospital (RCWMCH) Oncology service changed 
from a BFM-87 based protocol to one based on MRC-AML15 in 2007 due to the poor 
outcomes achieved for patients with standard and poor risk acute myeloid leukaemia (AML). 
This study was designed to assess the interim outcomes and treatment – related toxicity 
among children treated with RCWMCH protocol Rx 2071.   
Procedure: 
This was a retrospective review of AML patients treated with Rx2071 between 2007 and 
2012 at RCWMCH. Patients with acute promyelocytic leukaemia (APL) and Down syndrome 
were excluded. Risk was assigned by cytogenetics. Good risk patients were those with t(8;21) 
and inv(16). Poor/standard risk included all other cytogenetics according to MRC-AML15.  
 Results: 
Thirty five children were treated on Rx 2071 during the study period. Males comprised 
51.4% (18/35) and females 48.6% (17/35). Age at diagnosis ranged from 0.33 to 12.51 years 
with the median being 5.68 years.  Follow-up from remission in the alive patients ranged 
from 1 year 10 months to 9 years 1 month with a median of  62.5 months. Fifteen patients 
had favourable cytogenetics. EFS for the good risk group was 85.6%.Twenty patients 
presented with standard/poor risk cytogenetics. EFS in this group was 32.4%. Patients had a 
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median of four neutropaenic fevers, and required a median of eight packed cell and 11 
platelet transfusions. There were 39 positive blood cultures.  
Treatment related deaths were 8.57%.  
Conclusion: 


















Acute myeloid leukaemia (AML) accounts for approximately 15 – 20% of acute leukaemia in 
children and adolescents. [1] The progress in treating AML has lagged behind that of acute 
lymphoblastic leukaemia (ALL). [2 ] Prior to 1970 nearly all patients with AML succumbed 
to their disease. [1,3] 
The Red Cross War Memorial Children’s Hospital (RCWMCH) Oncology Service had poor 
results in treating AML and this prompted a change in protocol in 1994. A Berlin Frankfurt 
Munster (BFM-87) based protocol, Rx 2941 was introduced. The outcome for the standard/ 
poor risk patients was an event free survival (EFS) of 27.3%. [4 ] The EFS for good risk 
patients was 74.4%. This protocol also resulted in 9% of the patients succumbing to toxicity 
related deaths. [4] As a result in 2007, United Kingdom’s Medical Research Council (MRC) 
AML 15 based protocol, Rx 2071, was adopted.   
Methods 
This was a retrospective analysis of all patients with AML treated on Rx 2071 at RCWMCH 
between 2007 and 2012. Patients with acute promyelocytic leukaemia (APL) and Down 
syndrome were excluded from the analysis because they were treated on different protocols. 
Patients with APL received Rx2091 which includes all trans retinoic acid (ATRA) in 
induction and 6 – mercaptopurine and methotrexate in maintenance. 
RCWMCH is an academic referral hospital attached to the University of Cape Town. The 
oncology unit treats children from the Eastern and Western Cape provinces. The hospital is a 
state funded institution and about 75% of the patients attending the oncology unit do not have 
medical insurance. The oncology unit sees 130 new patients each year. There are three full 
time oncologists, a reliable supply of chemotherapeutic agents, blood products and broad-
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spectrum antibiotics as well as access to comprehensive support services including radiology 
with magnetic resonance imaging (MRI) capability, intensive care, cardiology, nephrology 
and dietetics. Patients who need allogeneic haematopoietic stem cell transplant (allo-HSCT) 
are sent to the transplant unit at Groote Schuur Hospital (3.8km away), which services adults 
and children.  
Risk was assigned by cytogenetics. Good risk patients were those with t(8; 21), inv(16) and 
t(16;16). The following cytogenetic patterns were deemed to be poor risk: monosomy 5 or 7   
del(5q), abn(3q),t(9;22) and major karyotype aberrations (>5 abnormalities). Standard risk 
cytogenetics consisted of cytogenetic patterns which were neither good nor poor risk. Patients 
who had more than 15% blasts on their day 28 bone marrow biopsies were also deemed poor 
risk. The risk assignment was as per the MRC – AML 15. [5, 6] 
Rx2071 comprises of two ADE induction blocks of cytarabine (100mg/m
2
 per dose), 
daunorubicin (50mg/m
2
 x 3) and etoposide (100mg/m
2
 x 5). ADE 1 has 20 doses of 
cytarabine while ADE 2 has 16 doses. A bone marrow aspirate and trephine is performed on 
day 28 of ADE 1. A patient is deemed poor risk if there are >15% blasts on the day 28 
marrow irrespective of cytogenetics. The two consolidation blocks consist of high dose 
cytarabine. (3g/m
2
 x 6) Patients who are in the standard/poor risk group are tissue typed and 
proceed to allo – HSCT after ADE 2 if a donor is available. If a sibling donor is not available, 
a donor is sought for on the local registry (or the international registry for insured patients). 
Mitoxantrone and intermediate dose cytarabine (1g/m
2
) are reserved for poor risk patients 
with no donor option. (Figure 1)  The cumulative anthracycline dose for the standard arm is 
300mg/m
2
. Triple intrathecal therapy (methotrexate, cytarabine and hydrocortisone) is given 
on day one of both ADE blocks. In the event of blasts in the diagnostic cerebral spinal fluid 
(CSF) triple intrathecal therapy is given twice weekly until the CSF is clear. An additional 
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two are given after the CSF has cleared and intrathecal therapy is administered monthly until 
the end of chemotherapy.  
Neutropaenic fever in our unit was defined as two axillary temperatures of >/= 37.5 degrees 
Celsius on two occasions or one axillary temp of >/= 38 degrees Celsius in a patient with an 
absolute neutrophil count of less than 1000 per microlitre. This differs from international 
guidelines. [7] This policy has been consistent during the use of  Rx2071 and Rx2941. We 
have instituted this policy to ensure that the vulnerable children in our setting are picked up 
early and started on appropriate anti microbials. An episode of prolonged neutropaenic fever 
was defined as one lasting for more than seven days.[8]   Blood cultures were obtained in an 
aseptic manner in patients with neutropeanic fever. The blood cultures were sent to the 
National Health Laboratory Service (NHLS). Here they were processed and analysed using 
the BACTEC
TM
 9240 automated blood culture system. Patients with febrile neutropaenia 
were started on empiric antibiotics ( pipericillin/tazobactam and amikacin.) 
 Patients with AML all received co- trimaxazole as pneumocystis prohylaxis. Patients with 
prolonged neutropaenia were started on prophylactic oral fluconazole. This has been the 
standard of care in our unit during the use of both Rx2941 and 2071. 
 
Blood products for transfusion were obtained from the Western Province Blood Transfusion 
Service. Packed red cell transfusions were given to patients with symptomatic anaemia or 
those with a haemoglobin (Hb) of seven grams per decilitre or less. Leucodepleted red cells 
were reserved for patients who were due to undergo stem cell transplantation. Platelet 
transfusions were given to patients who were actively bleeding or to those with platelets of 50 
000/mm
3
 in the face of severe mucositis or 20 000 /mm
3
 and falling after chemotherapy. 
Apheresis single donor units of platelets were given to patients who reacted to pooled 
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platelets and those who were to undergo stem cell transplantation. The volumes of these units 
are approximately 275 millilitres (ml). Those patients not due for stem cell transplant 
received pooled units of platelets. One pooled unit of platelets is approximately 200ml.    
Current outcomes were defined as follows: alive disease free (ADF), alive with disease 
(AWD), died due to disease (DD) and died due to another cause (DO). 
Post remission follow up was defined as the time elapsed from first complete remission 
(CR1) to the latest follow up date or date of death. 
Complete remission was defined as a bone marrow with <5 % blasts morphologically. 
Data was obtained from patient folders and entered into a Microsoft Access
TM
 database. 
Descriptive analyses were performed using Excel
TM
. EFS was calculated with Statistica
TM
. 
Kaplan – Meier curves were used to determine the EFS.  EFS was calculated from the point 
of diagnosis to the date of an event (relapse or death) or the last follow up date.  The 
standard/poor risk and good risk groups were compared using the log – rank test. A p value of 
0.05 was regarded as statistically significant. 
Ethics approval was obtained from the Human Research and Ethics committee at the 
University of Cape Town. The ethics reference number is HREC REF: 235/2012. 
Results 
Thirty five children were treated on Rx 2071 from 2007 to 2012. Males comprised 51.4% 
(18/35) and females 48.6% (17/35). Ages ranged from 0.33 to 12.51 years with the median 
age being 5.68 years.  
Fifteen patients were in the good risk cytogenetics group with 14 having t(8;21) and one with 
inv(16). Twenty patients were in the standard/poor risk group. Nineteen patients had standard 
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risk cytogenetics. One patient with major karyotype aberrations (MAKA) was poor risk.  
Four patients did not achieve remission, one of whom presented with intracranial 
haemorrhage and died early in induction. Thirty one patients achieved CR1 (good risk: n= 15; 
standard/poor risk: n= 16). Two of the standard/poor risk patients were transplanted in CR1:  
one demised due to graft-versus-host-disease (GvHD). Ten patients relapsed (good risk: n= 2; 
standard/poor risk: n=8). Two patients received matched sibling allo – HSCT in CR2 (good 
risk: n= 1; standard/poor risk: n=1): one demised due to delayed onset acute GvHD. Twenty 
one patients are currently alive and disease free. (Figure 2) 
Overall EFS was 54 %. (Figure 3) EFS for the good risk group was 85.6%. EFS for the 
standard/poor risk group was 32.4 %. (Figure 4) This difference was statistically significant 
(p value 0.003). (Figure 4) 
Follow–up from remission in the patients who survived ranged from 1 year 10 months to 9 
years 1 month with a median of 62.5 months.  
Standard and poor risk patients are tissue typed and proceed to allo – HSCT after ADE2 if a 
donor is available. The donor pool for our patients was small. We had access to matched 
siblings and a limited number of matched unrelated donors on the South African Bone 
Marrow Registry (SABMR), which currently has 73000 registered donors but does not 
adequately represent the ethnic diversity of our patient population. [9] Only those patients 
with health insurance had access to international donors and thus many patients who qualify 
for allo – HSCT  cannot access a transplant. [9]  
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Two of the twenty standard/poor risk patients eligible for allo – SCT were transplanted in 
CR1. One had a matched sibling allo – HSCT, relapsed and received a second allo – HSCT 
from the same donor in CR2. This patient is currently alive and disease free. The other patient 
received an unrelated cord allo – HSCT and died due to GvHD.   
Two standard/poor risk patients had matched sibling donors but were not transplanted in 
CR1. One of these patients had two matched sibling donor options but the family refused the 
allo – HSCT and this patient is well and disease free. The other patient had one matched 
sibling donor but never achieved CR1. The remaining 16 standard/poor risk patients had no 
sibling donor options; three of them failed to achieve CR1, six remain in CR1 and seven 
relapsed. 
Two patients were transplanted in CR2. One was a good risk patient who received a matched 
sibling allo – HSCT. This patient demised due to late onset acute GvHD. The other was the 
standard/poor risk patient who had received a matched sibling allo – HSCT in CR1. Eight 
patients who relapsed did not receive an allo – HSCT. Two had potential donors on 
accessible registries but never achieved CR2. The remaining six patients had no donor 
options and were palliated. 
 
There were 135 episodes of neutropaenic fever with a median of four episodes per patient and 
67.4% (91/135) met the case definition for prolonged neutropaenic fever while 32.6% 
(44/135) lasted fewer than seven days. There was a minimum of two episodes of 
neutropaenic fever per patient, excluding one patient who died early in induction. There were 
32 positive bacterial blood cultures with a range of 0 to 4 positive cultures per patient. Gram 
positive organisms were most frequently cultured with Staphylococcal species accounting for 
ten cultures, Streptococcal species accounting for eight and Enterococci for one. Only two of 
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the streptococcal infections occurred after high dose cytarabine. Thirteen cultures grew gram 
negative bacilli, with one patient requiring inotropes. There were seven positive fungal blood 
cultures which were successfully treated with systemic anti fungals. One patient had mucor of 
the appendix and survived after complete resection of the affected area and systemic 
amphotericin B. It is standard of care in our unit for patients with AML to have central 
venous access devices but this study did not look at whether the positive blood cultures were 
from peripheral or central samples.  Other recorded infections included two urinary tract 
infections, one liver abscess, one giardia gastroenteritis, one scalp abscess and one 
thrombophlebitis.  
 
There was a mean of 7.8 and a median of eight packed cell transfusions per patient, with a 
range of 1 to 15.  There was a mean of 11.3 and a median of 11 platelet transfusions per 
patient, with a range of 3 to 19.  
There were no cases of cardiomyopathy.  
There were 3 treatment related deaths. One patient presented with intracranial haemorrhage 
as a complication of disease prior to starting chemotherapy and died early in induction. Two 
patients succomed to GvHD post allo –HSCT. The treatment related toxicity was 8.57%.  
 
Discussion 
The progress in treating AML has not kept pace with developments in ALL. [2] A recent 
report demonstrated that five year overall survival (OS) rates in AML range from 50% - 76%. 
[10] There has, however, been steady progress leading to improved survival. [3,11,12,13] 
Some of the key factors contributing to the improved survival are the addition of cytarabine 
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and anthracyclines to chemotherapy regimens, [1,3] the formation of collaborative study 
groups, [10] improvements in supportive care [3,10,13] and the use of stem cell 
transplantation. [3,14,15] 
Prior to 2007 patients with AML at RCWMCH were treated on a modified BFM-87 protocol, 
Rx 2941. This protocol consisted of four blocks of intense chemotherapy (induction, 
consolidation and two intensification blocks) as well as one year of maintenance therapy with 
thioguanine and cytarabine. The induction block of ADE was followed by a consolidation 
block consisting of six weeks using six drugs.  The two intensification blocks consisted of 
high dose cytarabine and etoposide. CNS prophylaxis was given in the form of methotrexate 
intrathecal therapy during induction and cytarabine intrathecal therapy during consolidation. 
(Figure 5) Rx2071 differs in that it only has four blocks of chemotherapy.  The consolidation 
blocks do not include etoposide but use high doses of cytarabine. Rx 2071 uses 
anthracyclines and cytarabine as its backbone and these drugs have been attributed to the 
improved survival in AML. [1,3] The total treatment time on Rx2071 is considerably shorter 
and this impacts positively on patient experience and workload without detracting from 
survival. Rx2071 also uses triple intrathecal therapy which may confer better CNS coverage. 
The EFS for good risk patients was 85.6% on Rx2071 as compared to an EFS of 74.4% on 
Rx2941 (p- value 0.25). The EFS of the standard/poor risk group was 32.4% compared to 
27.3% on Rx2941 (p-value 0.4) ( Table 1) Rx2071 did not have excessive toxicity.(Table 1) 
The EFS for good risk patients is excellent but the EFS for the standard/poor risk group are 
not on par with results being achieved in high income countries. [10] 
As mentioned before, international experience suggests that stem cell transplant has 
positively impacted on survival. [14,15] The role of allo- HSCT in CR1 has led to debate 
among various study groups. [9,16] Since the mid-eighties allo- HSCT has been 
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recommended for patients with matched sibling donor following induction chemotherapy, 
[16,17,18,19,20] but there are no randomized clinical trials comparing allo– HSCT to 
chemotherapy. [12,16] There is general consensus among the various study groups that 
patients with APL, Down syndrome and those with t(8,21), inv(16) or t(16,16) do not need 
allo- HSCT in CR1 [15,16] and that poor risk patients do need allo– HSCT in first remission. 
[9,21] 
Our limited experience with transplantation in this group of patients prevents us from 
drawing any absolute conclusions about the benefits of this salvage strategy but we would 
still pursue transplantation in end-induction unremitted patients or those with standard or 
poor risk cytogenetics who have a suitable donor, as this likely offers the only chance of 
survival for these patients.  The relative paucity of  adequate  local donor genotypes on the 
SABMR [9] and the fact that only those patients with health insurance have access to donors 
on international registries  has resulted in  very few of our patients being transplanted.  A 
similar phenomenon emerged when looking at a historical cohort of patients who were 
treated on the previous BFM based protocol at RCWMCH. Of the 45 patients considered for 
allo – HSCT on Rx2941, only three were transplanted. [4]  
The toxicity related deaths in Rx2071 were 8.57% . Only one of these deaths were in 
induction and this patient had presented with an intra cranial haemorrhage. Two patients died 
due to GvHD  post transplant and these were thus not attributed directly to the chemotherapy 
on Rx2071. Toxicity related deaths accounted for 9% of the 78 patients treated on the 
previous BFM based protocol at RWMCH between 1994 and 2005. [4] These deaths were 
due to gram negative sepsis (n=3),fatal haemorrhages ( n=2), treatment related 
myelodysplasia (n=1 ) and cardiomyopathy ( n=1).  AML studies in the past have shown 
relatively high mortality related to the leukaemia and treatment complications. [10,22,23,24 ] 
The Dutch Childhood Oncology Group found that they had higher treatment related mortality 
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with an increased intensity of their chemotherapeutic regime on their AML 92/94 protocol. 
[23] Patients with AML are at risk of invasive fungal infections, viridans streptococcal  [ 25 ] 
and gram negative bacteraemias. [10,26 ] AML patients with hyperleukocytosis ( white blood 
cell count > 100 x 109/L) are at increased risk of pulmonary leucocytosis, CNS ischaemia 
and haemorrhage resulting in early death. [10] Our study found that gram positive organisms 
were most commonly cultured . This is in keeping with other studies. [25,27,28,29] None of 
our patients succumbed to infection. Treatment related toxicity on Rx2071 was deemed 
acceptable given our supportive care architecture.   
Good supportive care is essential in treating patients with intense chemotherapy regimens. 
[30,31] Supportive care at RCWMCH has improved over the years with more nursing staff 
being oncology trained. There is also comprehensive multi –disciplinary supportive services. 
We have fungal and antimicrobial prophylaxis policies and strict protocols for neutropaenic 
fever. This has contributed in decreasing toxic deaths. 
The late Robert Arceci suggested that the ideal remission – reduction regimen is one that 
effectively results in cytoreduction without significant toxicity to the patient and has a 
positive impact on post remission treatment. [1] This treatment protocol goes some way to 
achieving this objective although room for improvement still exists in standard and poor risk 
patients.  
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TABLE 1 Event free survival (EFS) and toxicity differences between  BFM 87 – based 






BFM = Berlin Frankfurt Munster; EFS = event free survival; MRC =Medical Research Council 































EFS: good risk cytogenetics 
 
74.4% (n= 29/37) 85.6%  (n= 13/15) 
EFS: standard/poor risk 
cytogenetics 
 
27.3% ( n= 13/41) 32.4% (n= 7/20) 
Neutropeanic fevers 
 
Mean = 3.3 Median = 3 Mean = 3.9 Median = 4 
Packed cell transfusions 
 
Mean = 8.2 Median = 7 Mean = 7.8 Median = 8 
Platelet transfusions 
 
Mean = 8.9 Median = 8 Mean = 11.3 Median = 11  
Toxicity related deaths 
 
9% (n= 7/78) 8.57% (n=3/35) 
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RX 2071  RED CROSS CHILDREN'S HOSPITAL ONCOLOGY SERVICE 
 
ACUTE MYELOID LEUKAEMIA      (2007) 
       (excluding Acute Promyelocytic Leukaemia) 
               Protocol based on MRC AML15 
Good Risk:  t(8;21)   inv(16)   t(16;16) 
Standard Risk: all patients that are neither good nor poor risk with BM < 15% blasts after ADE 1 
Poor Risk:   monosomy 5 or 7   del(5q)   abn(3q)   t(9;22)   MAKA(>5abn)  or  BM > 15% blasts after ADE 1  
All but good risk cytogenetics should be considered for MRD BMT in 1st remission 
 
                IT Therapy:                     Methotrexate                     1yr 5mg / 1-2yr 7.5mg / 2-3yr 10mg / >3yr 12.5mg 
   Cytarabine  1yr 15mg / 1-2yr 20mg / 2-3yr 25mg / >3yr 30mg 
   Hydrocortisone 1yr 5mg / 1-2yr 7.5mg / 2-3yr 10mg / >3yr 12.5mg 
                 Cotrimoxazole prophylaxis 80 mg TMP/m2 po BD three days weekly [0-6m: 2.5ml / 6m-6y: 5ml / >6y: 10ml] 
  
1 INDUCTION  
                ADE 1 
 Day 1-10  Ara C 100 mg/m2 over 30 minutes 12 hourly [20] 
 Day 1,3,5  Daunorubicin 50 mg/m2 IV over 1 hour [3] 
 Day 1-5  Etoposide 100 mg/m2 IV over 2 hours daily [5] 
 Day 1  Triple IT (doses above)  
 Bone Marrow at day 28 or when ANC > 0.5; Tissue typing after remission if full siblings 
                 ADE 2 Requires ANC > 1 and Platelets > 100 at Day 1 
 Day 1-8  Ara C 100 mg/m2 over 30 minutes 12 hourly [16] 
 Day 1,3,5  Daunorubicin 50 mg/m2 IV over 1 hour [3] 
 Day 1-5  Etoposide 100 mg/m2 IV over 2 hours daily [5] 
 Day 1  Triple IT (doses above) 
                 Bone Marrow after ADE 2 if > 15% blasts after ADE 1  
      2        CONSOLIDATION 
                HDAC  Requires ANC > 1 and Platelets > 100 at Day 1 
 Day 1,3,5  AraC 3 g/m2 IV over 3 hours 12 hourly [6] (start pm)  
 prednisone eye drops 3 hourly for 6 days and then 6 hourly for a further 4 days 
  
        HDAC 2 Requires ANC > 1 and Platelets > 100 at Day 1 
 Day 1,3,5  AraC 3 g/m2 IV over 3 hours 12 hourly [6] (start pm)  
                prednisone eye drops 3 hourly for 6 days and then 6 hourly for a further 4 
                For Central nervous system disease  (>5 cells per hpf with blasts on cytospin): 
 2x weekly IT therapy until CSF clear plus two (minimum of 6) then monthly IT until the end of chemotherapy 
 18 Gy of cranial radiotherapy 
  
 For poor risk AML with no matched donor substitute HDAC 2 with MidAc 
  
        MidAc Requires ANC > 1 and Platelets > 100 at Day 1; Requires normal cardiac function on echocardiogram 
                                                                                                         
 Day 1-5                                                                                       Mitoxantrone 10mg/m2 IV over 1 hour daily [5] 
 
        Day 1-3                                                                                         AraC 1g/m2     IV over  2 hours 12hourly [6]                                
               prednisone eyedrops 3 hourly for 5 days and then 6 hourly for   further 5 days 
 
 
FIGURE 1 MRC AML 15- based Rx2071 treatment protocol 
ADE= cytarabine, daunorubicin,etoposide;ANC= absolute neutrophil count; CSF =cerebral spinal 
fluid;  HDAC= high dose cytarabine; IT= Intrathecal; MidAc= mitoxantrone and cytarabine; MRC= 


























































FIGURE 2 Consort diagram of Acute myeloid leukaemia (AML) patients treated on 
Rx2071 between 2007 and 2012 
CR1= first complete remission; CR2 = second complete remission;GvHD = graft-versus-





 Patients (n=35) 
Good risk: n=15 
Standard/Poor risk: n=20 
 
No Remission: n=4 
Achieved Remission (n= 31): 
Good risk: n= 15 
Standard/Poor risk: n= 16 
Allo-HSCT in CR1: 





Alive, disease free: 
Good risk: n= 13 
Standard/Poor risk:  n= 7 
Relapse: 
Good risk: n = 2 
Standard/Poor risk: n = 8 
Did not achieve 
CR2 and demised: 
Good risk: n=1 
Standard/Poor risk: 
n=7 
Achieved CR2 and 
received allo – 
HSCT: 
Good risk: n = 1 
Standard/poor risk:    
n = 1 
Alive, disease free: 
Standard/Poor risk: n = 1 
Demised: 
Good risk: n = 1 (delayed onset 








FIGURE 3 Event free survival of all patients treated on Rx2071 between 2007 and 2012  
AML= acute myeloid leukaemia; EFS= event free survival; n= number of patients; RCCH= 






















FIGURE 4 Event free survival based on cytogenetic risk groups 
AML= acute myeloid leukaemia; EFS= event free survival; n= number of patients; RCCH= 



















RED CROSS CHILDREN'S HOSPITAL ONCOLOGY: ACUTE MYELOID LEUKAEMIA RX2941  (1994) 
Protocol based on BFM 87. All but good risk cytogenetics should be considered for BMT in 1st remission
Bactrim prophylaxis 80 mg TMP/m2 po BD three days weekly [0-6m: 2.5ml / 6m-6y: 5ml / >6y:10ml]
1.INDUCTION
Day 1,2 Ara C 100 mg/m2 IV over 24 hours by continuous infusion 
Day 3-8 Ara C 100 mg/m2 IV over 30 minutes 12 hourly [12] 
Day 3-5 Daunorubicin 30 mg/m2 IV over 1 hour 12 hourly [6] 
Day 6-8 Etoposide 150 mg/m2 IV over 1 hour daily [3] 
Day 1 Methotrexate IT …
Age <1yr 5mg / 1-2yr 7.5mg / 2-3yr 10mg / >3yr 12. 
  Bone Marrow at day 28 or when ANC > 0.5 ; Tissue typing after remission if full siblings 
2.CONSOLIDATION Requires ANC > 1 and Platelets > 100 at Day 1 
Weeks 1-4 
Day 1, 8, 15, 22 Vincristine 1.5 mg/m2 IV (maximum 2 mg) 
Adriamycin 30 mg/m2 IV over 30 mins 
Day 2-5, 9-12, 16-19, 23-26 Ara C 75 mg/m2 IV or sc 4 days weekly 
Day 1-28 Prednisone 40 mg/m2 po daily (wean over 5 days) 
Day 1-28 Thioguanine 60 mg/m2 po daily 
Day 1,15 Ara C IT …
       Age <1yr 10mg / 1-2yr 15mg / 2-3yr 20mg / >3yr30mg 
Push through as quickly as possible; Delay each weekly block if plts < 50 or granulocytes < 0.5 
TG dose reduction:50% if plts 50-100 or ANC 0.5-1; STOP if plts < 50 or ANC < 0.5 
Weeks 5 and 6 Requires ANC > 1 and Platelets > 100 at Day 29 and 36 
Day 29, 43 Cyclophosphamide 500 mg/m2 IV with post-hydration 
Day 30-33, 37-40 Ara C 75 mg/m2 IV or sc 4 days weekly 
Day 29-43 Thioguanine 60 mg/m2 po daily 
Day 29, 43 Ara C IT …
Age <1yr 10mg / 1-2yr 15mg / 2-3yr 20mg / >3yr 30mg 
TG dose reduction:50% if plts 50-100 or ANC 0.5-1; STOP if plts < 50 or ANC < 0.5 
3 INTENSIFICATION I and II Requires ANC > 1 and Platelets > 100 at Day 1
Day 1-3 Ara C 3 g/m2 IV over 3 hours 12 hourly [6] 
Day 2-5 Etoposide 125 mg/m2  IV over 1 hour daily [4] 
Day 1-5 Steroid eye drops 3 hourly  
Day 6-10 Steroid eye drops 6 hourly 
4 CONTINUATION Requires ANC > 1 and Platelets > 100 
Day 1-28 Thioguanine 40-60 mg/m2 po daily 
Day 1-4 Ara C 50 mg/m2 IV or sc  
TG dose reduction:50% if plts 50-100 or ANC 0.5-1 
STOP if plts < 50 or ANC < 0.5 
Repeat continuously for 12 months 
Figure 5 BFM 87 based Rx2941 treatment protocol 
ANC= absolute neutrophil count; BMT =bone marrow transplant; CSF =cerebral spinal fluid; IT 




 Appendix 1: Study Protocol 
Interim analysis of Acute Myeloid Leukaemia treated on the Red Cross Children’s 
Hospital Rx 2071 (adapted from the MRC AML 15 protocol) 
 
Background: 
Acute myeloid leukaemia (AML) accounts for approximately 15 – 20% of acute leukaemia in 
children and adolescents.[1]
  AML is a heterogenous family of neoplasms involving the precursor cells of myeloid 
lineage.[1 ,2]It is characterised  by proliferation of the myeloid precursors with an inability of 
these cells  to differentiate into mature elements.[2] 
The cure rates for AML vary between 40 and 50%, [1, 3] lagging behind the progress that has 
been made in the treatment of acute lymphoblastic leukaemia (ALL). [3] 
The history of AML treatment is very interesting. Before 1970 nearly all those with AML 
died of their disease. [1] Anthracyclines and cytarabine were introduced in the 1970s and 
1980s and their use resulted in a minority of patients being cured.
 
[1] The 5 year survival rate 
of children younger than 15 with AML until the early 1990s was poor at 28%. [1] There has, 
however, been an improvement in the prognosis of AML over the last few decades. 
[4]Various clinical trials have looked at different treatment regimens for AML. The trials in 
the 1990s intensified the doses of traditional chemotherapeutic agents. [1] These trials all had 
similar stages of therapy namely: remission induction, consolidation and intensification with 
or without maintenance. The journal, Leukemia, invited groups from all over the world in 
2005 to describe their experiences on treating AML.[4] 
 
These group utilized a similar 
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approach:  risk – adapted therapy, consisting of  dose – intense blocks using common drugs  
(cytarabine, anthracycline and etoposide).[4]
 
There were, however,  many differences  such 
as,  the design, intensity and number of blocks given, the use of maintenance treatment, the 
cumulative doses of the most important drugs given, the use of intrathecal therapy and cranial 
irradiation for prophylaxis of central nervous system  (CNS) relapse and the indications for 
stem cell transplantation. [4]
 
What proved vital to their success, regardless of the specific 
approach was an improvement in their capacity for supportive care, which decreased deaths 
from toxicity. All these groups reported that they had an improved outcome with a decline in 
early deaths, an increase in complete remission and a decrease in relapse rates; the net result 
being an increase in event free survival (EFS).[4] 
 
The various treatment strategies have presented numerous questions which were highlighted 
in a recent review article by RJ Arceci. [1]
 
Some of these questions are: what is the optimal 
remission – induction regimen?; how many courses of chemotherapy are needed to cure 
AML; is there a role for maintenance therapy? What is the optimal therapy for reducing CNS 
relapse? [1] Some studies have showed that there is no benefit of maintenance therapy.[4] 
despite the fact that the Berlin – Frankfurt – Munster ( BFM) group use a maintenance block 
in their treatment.[5]The Red Cross Children’s Hospital AML treatment protocol from 1994 
– 2007 was adapted from the BFM 87 protocol. All studies have experienced success with 
intensifying doses but there is no consensus on how many courses of the chemotherapy are 
ideally needed.[1] The BFM 87 trial showed that patients receiving cranial irradiation had a 
better relapse – free survival.[1,5]
 
 This was in contrast to many other studies such as the 
MRC, POG and CCG trials. These studies did not include cranial radiation and they had 
similar outcomes to the BFM 87 trial.[1,6,7]Robert Arceci in his review article suggests that 
the ideal remission – reduction regimen is one that effectively results in cytoreduction 
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without significant toxicity to the patient and one which has a positive impact on post 
remission treatment. [1]
 
Unfortunately, no such perfect regimen exists presently. [1]
 
The Red Cross Children’s Hospital Oncology Service had poor results in treating AML and 
this prompted a change in protocol in 1994. [8] A BFM 87 based protocol, Rx 2941 was 
introduced. However, the outcome for the poor risk patients was poor with an EFS of 
27.3%.[9]The EFS for good risk patients was 74.4%.  This resulted in yet another change in 
AML treatment protocol and in 2007 a MRC – AML 15 based protocol, Rx 2071 was 
adopted. In the United Kingdom the Medical Research Council (MRC)  has conducted trials 
using various treatment regimens.  The MRC AML 10 trial used four blocks of chemotherapy 
and assessed the role of allogenic and autologous bone marrow transplant. This trial found 
that bone marrow transplant reduced relapse risk but did not contribute to an increase in 
overall survival.[6]
 
The MRC AML 12 trial tested whether or not an extra course of 
chemotherapy would be beneficial and it found that there was no advantage in an extra 
course.[6] In this trial allogenic bone marrow transplant was offered to the standard and poor 
risk patients.[6] The MRC AML 15 trial compared an anthracycline based consolidation with 
a Cytosine – Arabinoside (cytarabine) based one.[10] 
 
It, thus will ask a particularly 
important question : how will the potentially less cardiotoxic  Ara – C based consolidation 
compare to the standard but potentially cardiotoxic anthracycline based one? [10]
 
As stated 
before Red Cross adopted an MRC based protocol in 2007 (see addendum 1). This protocol 
uses the cytarabine based consolidation arm ( see addendum 2) . 
 
Risk stratification is important.  As suggested before, trials have offered certain treatment 
strategies based on risk. The BFM group looked at risk and found that certain cytogenetic 
patterns were associated with a favourable outcome. [11]The cytogenetic patterns deemed 
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good risk were: t(8;21), t(15;17) and inv16.[11]The prognostic accuracy of good risk 
cytogenetics has been widely reported and was demonstrated at Red Cross Children’s 
Hospital with Rx 2941.[9]
  
As stated before it is important to that one has the most effective treatment regime without 
significant toxicity. At Red Cross Children’s War Memorial Hospital (RCCWMH) the 
toxicity related deaths with Rx 2941 was 9%. [9]  
 
The RCCWMH AML protocol Rx2071 has now been used for four years. Although we can’t 
yet ascertain the true 5-year EFS, it is necessary to perform an interim analysis to ensure that 




To assess the interim outcomes of patients with AML, treated on the new AML treatment 
regime, Rx 2071 adopted by Red Cross Children’s Hospital from 2007. 
Objective: 
The objectives of this analysis are: 
- To determine the number ofstandard/ poor risk and good risk AML patients as defined by 
cytogenetics    
- To assess the event free survival ( EFS)  of  both poor/standard risk  and good risk 
patients ( as defined by cytogenetics) on the new AML treatment regimen 
- To determine the toxicity associated with the new AML regimen 
 Methods 
Study Design: 
This will be a retrospective folder review. 
Sample: 
All patients with AML treated at Red Cross Children’s hospital on the AML regime Rx 2071 
from 2007 to 2012. Patients with Down Syndrome will be excluded, and patients with Acute 











A database will be created in Microsoft access onto which various variables will be captured. 
The variables will be listed under columns. Each row will represent a patient. The variables will 
be as follows: 
A: Patient folder number 
B: Patient surname 
C: Patient name 
D: Date of diagnosis 
E: Date of birth 
F: Sex 
G: FAB 
H: FAB code 
I: Immunophenotype 
J: Cytogentics 
K: Cytogenetics risk group 
L: Karyotype 
M: FISH 
N: Remission achieved 
O: Date of remission achieved 
P: Treatment protocol used 
Q: Neutropaenic fever 
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R: Positive blood cultures 
S: Myelotoxicity 
T: Follow up date 
U: Currently 
The data will be collected from the patients’ folders. 
Analysis: 
Descriptive analyses will be performed using Microsoft Access and Excel. Event free survival 
will be calculated using Statistica. Kaplan – Meier curves will be used to determine the EFS.  
EFS will be calculated from the point of diagnosis to the date of an event (relapse or death) or 
the last follow up date.  The normal/poor risk and good risk groups will be compared using the 
log – rank test. A p – value of 0.05 will be regarded as statistically significant.  
Ethics and Communication: 
This is a retrospective study therefore informed consent from each patient is thought to be 
unnecessary. The names of the patients will not be published or used in any presentations. This 
study does implement the ethical principle of beneficience. This study will benefit those patients 
with AML because it will determine whether or not the current treatment protocol is an 
improvement on the old regime based on event free survival.  
This study will serve as the mini dissertation for an MPhil project. The results of this study will 
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 Protocol Addendum 1: 
 RED CROSS CHILDREN'S HOSPITAL ONCOLOGY SERVICE 
    ACUTE MYELOID LEUKAEMIA (2007) 
 (excluding Acute Promyelocytic Leukaemia) 
Protocol based on MRC AML15 
Good Risk:  t(8;21)   inv(16)   t(16;16) 
Standard Risk: all patients that are neither good nor poor risk with BM < 15% blasts after ADE 1 
Poor Risk:   monosomy 5 or 7   del(5q)   abn(3q)   t(9;22)   MAKA(>5abn)  or  BM > 15% blasts after ADE 1 
All but good risk cytogenetics should be considered for MRD BMT in 1st remission 
IT Therapy: Methotrexate 1yr 5mg / 1-2yr 7.5mg / 2-3yr 10mg / >3yr 12.5mg 
Cytarabine 1yr 15mg / 1-2yr 20mg / 2-3yr 25mg / >3yr 30mg 
Hydrocortisone 1yr 5mg / 1-2yr 7.5mg / 2-3yr 10mg / >3yr 12.5mg 
Cotrimoxazole prophylaxis 80 mg TMP/m2 po BD three days weekly [0-6m: 2.5ml / 6m-6y: 5ml / >6y: 10ml] 
2 INDUCTION  
ADE 1 
Day 1-10 Ara C 100 mg/m2 over 30 minutes 12 hourly [20] 
Day 1,3,5 Daunorubicin 50 mg/m2 IV over 1 hour [3] 
Day 1-5 Etoposide 100 mg/m2 IV over 2 hours daily [5] 
Day 1 Triple IT (doses above)  
Bone Marrow at day 28 or when ANC > 0.5  
Tissue typing after remission if full siblings 
ADE 2 Requires ANC > 1 and Platelets > 100 at Day 1 
Day 1-8 Ara C 100 mg/m2 over 30 minutes 12 hourly [16] 
Day 1,3,5 Daunorubicin 50 mg/m2 IV over 1 hour [3] 
Day 1-5 Etoposide 100 mg/m2 IV over 2 hours daily [5] 
Day 1 Triple IT (doses above) 
Bone Marrow after ADE 2 if > 15% blasts after ADE 1 
2   CONSOLIDATION 
HDAC 1 Requires ANC > 1 and Platelets > 100 at Day 1 
Day 1,3,5 AraC 3 g/m2 IV over 3 hours 12 hourly [6] (start pm) 
prednisone eyedrops 3 hourly for 6 days and then 6 hourly for a 
further 4 days 
HDAC 2 Requires ANC > 1 and Platelets > 100 at Day 1 
Day 1,3,5 AraC 3 g/m2 IV over 3 hours 12 hourly [6] (start pm) 
prednisone eyedrops 3 hourly for 6 days and then 6 hourly for a 
further 4 days 
For CNS disease (>5 cells per hpf with blasts on cytospin): 
2x weekly IT therapy until CSF clear plus two (minimum of 6) then monthly IT until the end of chemotherapy 
18 Gy of cranial radiotherapy 
For poor risk AML with no matched donor substitute HDAC 2 with MidAc 
MidAc Requires ANC > 1 and Platelets > 100 at Day 1 
Requires normal cardiac function on echocardiogram 
Day 1-5 Mitoxantrone 10 mg/m2 IV over 1 hour daily [5] 
Day 1-3 AraC 1 g/m2 IV over 2 hours 12 hourly [6] 
prednisone eyedrops 3 hourly for 5 days and then 6 hourly for a 
further 5 days 
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Protocol Addendum 2: 
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FIGURE 1 Platelet count and absolute neutrophil count (ANC) versus time since diagnosis. Treatment courses are 
indicated at top with doses as described in Table 1: Vbl, vinblastine; Pred, prednisone; Ritux, rituximab; MP, 
mercaptopurine. IVIg = short course intravenous immunoglobulin 1 g/kg/day for 2 days, given for immune 
thrombocytopenia. 
 
Image from: Cooper, S. L., Arceci, R. J., Gamper, C. J., Teachey, D. T. and Schafer, E. S. (2015), Successful 
Treatment of Recurrent Autoimmune Cytopenias in the Context of Sinus Histiocytosis With Massive 
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--Decimal numbers should have a zero preceding the decimal point (e.g., 0.95g). 
--Decimal points should be periods and not commas. 
--Do not begin sentences with a number. For example, it should be “Three patients…” instead of “3 patients…” 
--Numbers over 999 must include a comma, e.g., 2,000. 
--P values should not be zero but refer to a number (e.g., p<0.0001 not p=0.0000). 
II. ARTICLE TYPES 













 Articles should represent original and in-depth 







 as needed  6 
PRIORITY 
REPORTS 
Upon approval by the journal’s editors, occasional 
timely and high-impact research articles may be fast-
tracked for online publication within 4 weeks after 
final acceptance and print publication within 2 
months of final acceptance. Cover letters for articles 
submitted as Priority Reports should include an 
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BRIEF REPORTS Brief reports may include descriptions of single or 
several patients that demonstrate novel findings or 
add in a significant way to current knowledge. Brief 
reports may also include novel laboratory 
observations relating to clinical questions or advances 
in laboratory methodologies. Brief reports should 
include the following sections: Introduction, Results 
(including Methods or Case Descriptions), and 












Reviews of important and timely subjects can be 
invited through the Editorial Board or submitted after 
a brief introduction to the Editor-in-Chief. Authors 
should consult the editor prior to submission by e-
mailing PBCeditorialoffice@wiley.com. The inquiry 
should include the authors’ names and affiliations, 
subject matter of the review, and rationale for 
publication in PB&C. Reviews should focus on the 
critical aspects of a subject, linking what is known to 
what areas remain controversial or unanswered. 
Historical accounts of important events relating to 
pediatric hematology/oncology are also acceptable. 
Requests for permission to submit manuscripts of 
greater length should be emailed to the Editor-in-











used only to 
provide 
summaries or 









Reviews of books, films or other media formats 
relevant to the scientific or clinical practice of 
medicine with particular importance to pediatric 
hematology/oncology can be invited or submitted 
independently. In the latter case, consultation with the 
Editor-in-Chief should be made prior to submission. 
N/A 1,000 
words  




made in the 
text. 
HIGHLIGHTS Highlights are submitted only at the invitation of the 
Editor-in-Chief. These will summarize findings from 
one or more recently accepted papers and put them 
into perspective in terms of past work and future 
challenges. Controversial areas should be included. 
 N/A  1,000 
words 





the content or 





COMMENTARY Commentaries are usually invited but may be 
submitted independently after consultation with the 
Editor-in-Chief. Commentaries should focus on a 
controversial subject or a timely topic of relevance to 
the journal’s readership. Commentaries will be 
reviewed and may require changes or be rejected. 
 N/A  1,200 
words 




made in the 
text. 
 CORRESPONDEN
CE AND LETTERS 
Letters to the Editor should usually be in reference to 
previously published manuscripts in Pediatric Blood 
and Cancer. Correspondence relating to important and 
timely publications or topics from other sources and 
brief descriptions of interesting laboratory or clinical 
















A Historical Perspective should be submitted only 
after consultation with the journal’s Editor-in-Chief. 
This occasionally-appearing series focuses on the 










These narratives, topical essays, historical vignettes, 
poems, and photographic essays will provide 
personal, artistic interpretations of the experiences of 
children with cancer or blood disease, or of caring for 
these children. Submissions may describe difficult, 
challenging, informative, or uplifting patient 
encounters or clinical experiences, or may explore 
other aspects of professional life in pediatric 
hematology/oncology. Like all work submitted to 
PBC, submissions should be original, and not 
previously published or under consideration 
elsewhere. 
Poems should be fewer than 50 lines and 400 words. 
N/A   1,200 
words 




made in the 
text. Photo 
essays may 
include up to 
6 images. 
 SPECIAL REPORT To be submitted only after consultation with the 
journal’s Editor-in-Chief, the report should focus on a 
subject of current interest to readers and/or 










CPGs should concern important and timely subjects. 
In 2011, the Institute of Medicine updated its 
definition of a CPG to reflect essential components of 
evidence-based guidelines: “CPGs are statements that 
include recommendations intended to optimize 
patient care that are informed by a systematic review 
of evidence and an assessment of the benefits and 
harms of alternative care options.” CPG submissions 
must receive pre-submission approval from the 
Editor-in-Chief. CPGs must meet the Institute of 
Medicine standards for trustworthiness as 
operationalized by the criteria for inclusion in the 
National Guideline Clearinghouse 
(http://www.guideline.gov/about/inclusion-
criteria.aspx). Criteria include, but are not limited to, 
recommendations being based upon a systematic 
review (the search strategy should be included as an 
Appendix) and the creation of evidence tables. Use of 
an approach for recommendation development such 
as Grades of Recommendation, Assessment, 
Development, and Evaluation (GRADE) is 
encouraged. An excellent resource for preparing a 
CPG can be found 
at:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC392
8232/. Guideline developers are encouraged to 
evaluate their own CPG using the Appraisal of 





















Concise summaries of meetings that have important 
information to convey to the readers of Pediatric 
Blood & Cancer are welcomed but consultation with 
the Editor-in-Chief should occur before submission. 
Summaries should emphasize the issues discussed at 














controversial. More extensive meeting reports with 
manuscripts from the speakers at the meeting are also 
welcomed but early consultation with the Editor-in-
Chief must take place in order to determine the type 
and number of manuscripts, expected pages to be 
published, and the review process, as well as 
procurement of additional funding if required. 
* Structured headings: (Background, Procedure, Results, and Conclusions) 
** Word count excludes title page, Abstract, References, Tables, Figures, and Legends 
*** Tables and figures should not simply repeat information in the text. Additional figures and tables can be included 
in Supplementary Materials 
MEETING ABSTRACTS 
*Abstract text should be 300 words or less. That word count excludes the abstract title, author names and affiliations. 
*There should be 4 sections to the abstract: Background/Objectives, Design/Methods, Results, Conclusion. All text 
should be included in a single paragraph and contain no lists. 
*Abstract text should be written in complete sentences and in correct English. 
*There should be a period at the end of all sentences. 
*Tables and figures (if allowed in the submitting society’s instructions), only when critical to the content, may be 
included and must comply with PBC Author Guideline format. 
*Abstract titles should be in all capital letters, e.g., INDUCTION OUTCOMES IN CHILDREN WITH ALL 
*Author names should be listed below the abstract title. The first and last names of authors should be written in upper 
and lower case letters and should be boldface. No degrees of authors should be included. 
*Author affiliations should be written in upper and lower case letters, e.g., Tata Memorial Centre 
*Geographic location should be indicated by city and country, with state, province, or other subdivision added if 
necessary for disambiguation, e.g. London, UK; but Portland, OR, USA. Names of cities and countries with 2 words 
should be written in upper and lower case letters, e.g., Czech Republic, South Africa, Los Angeles, St. Louis. 
Common abbreviations may be used, e.g. UK, USA. 
*Periods should be used in numbers for decimal points, not commas, e.g., P=0.015, and numbers beginning with a 
decimal point should be preceded by a zero. 
*Disease names should be written without apostrophes, e.g., Hodgkin lymphoma, Non-Hodgkin lymphoma, Burkitt 
lymphoma, Ewing sarcoma 
*Numbers containing more than 3 digits should have a comma, e.g., 3,000. 
*Abbreviations should be defined on first usage, then using of abbreviation alone is acceptable: e.g., Wilms Tumor 
(WT), then referred to as WT in subsequent mention, no quotation marks, however. 
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*Abstracts need to be proofread for all spelling and grammatical errors. 
*Abstracts that do not satisfy publication instructions will not be published. 
CLINICAL TRIALS 
- NOTE: Clinical trials can be submitted as either a Research Article or a Brief Report. There is not a separate article 
type for clinical trials. 
- Reporting prospectively conducted trials is strongly encouraged and such trials will be prioritized 
- Retrospective reporting of clinical data is potentially acceptable for publication. All such manuscripts need to comply 
with documentation of approval by an institutional ethical review board or equivalent. Retrospective therapeutic 
studies should be avoided, as they may circumvent necessary informed consent, safety, and monitoring standards. 
- All manuscripts reporting clinical trials need to document that the trial or study was approved Institutional Review 
Board or equivalent. 
- All manuscripts reporting clinical trials need to be registered with ‘ClinicalTrials.Gov’ and/or an equivalent site. 
NIH Public Access Mandate 
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy 
statement 
Wiley Author Licensing Services (WALS) 
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email 
prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able 
to complete the license agreement on behalf of all authors on the paper. 
For authors signing the copyright transfer agreement 
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer 
agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the 
Copyright FAQs below: 
 
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp 
For authors choosing OnlineOpen 
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons 
License Open Access Agreements (OAA): 
 
Creative Commons Attribution License OAA 
Creative Commons Attribution Non-Commercial License OAA 
Creative Commons Attribution Non-Commercial -NoDerivs License OAA 
 
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on 
Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.aspand 
visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html. 
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If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the 
Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license 
supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on 
this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement. 
For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license: 
Creative Commons Attribution License OAA 
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on 
Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.aspand 
visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html. 
For additional tools visit Author Resources - an enhanced suite of online tools for Wiley Online Library journal 
authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.  
